PrecisionLife advances long COVID diagnosis using AI technology

PrecisionLife announced advancements in diagnosing long COVID and other complex diseases using AI and combinatorial analytics. This approach identifies genetic and non-genetic factors, offering new insights into disease mechanisms and potential treatments. On International Long COVID Awareness Day, it was highlighted that there are currently no approved diagnostics or therapies for long COVID. PrecisionLife's research has uncovered significant genetic associations, including over 5,000 SNPs linked to long COVID, surpassing previous studies. The company is collaborating with the Metrodora Foundation on clinical studies involving 1,000 patients. They aim to provide personalized insights based on genetic risk signatures, potentially transforming treatment approaches for long COVID and related conditions.